| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Lycorine hydrochloride monohydrate targets MCL1, an anti-apoptotic protein of the BCL2 family. It also interacts with other key target genes such as AKT1. The compound acts by inhibiting protein synthesis and interfering with cell proliferation pathways.
|
|---|---|
| ln Vitro |
In vitro, lycorine hydrochloride monohydrate has demonstrated antiviral and antitumor activities. It modulates cellular pathways involved in apoptosis and cell proliferation. The compound shows significant anti-cancer properties in various tumor cell lines.
|
| ln Vivo |
In vivo, lycorine hydrochloride monohydrate has been investigated in animal models for its potential therapeutic effects. It exhibits antiviral, antitumor, and anti-inflammatory activities. The compound's effects on tumor growth and immune responses have been evaluated in preclinical studies.
|
| Enzyme Assay |
In vitro enzyme binding assays typically measure the interaction of lycorine with MCL1 or other target proteins. Surface plasmon resonance or isothermal titration calorimetry may be used to determine binding affinity. Alternatively, enzyme activity assays measure the inhibition of protein synthesis in cell-free systems.
|
| Cell Assay |
In vitro cellular assays evaluate the antiproliferative and cytotoxic effects of lycorine hydrochloride monohydrate on cancer cell lines. Cells are treated with varying concentrations of the compound for 48-72 hours, and cell viability is assessed using MTT or similar assays. Apoptosis is detected by Annexin V staining or caspase activity assays.
|
| Animal Protocol |
In vivo animal experiments are conducted in mouse xenograft models bearing human tumor cells. Lycorine hydrochloride monohydrate is administered via intraperitoneal or oral routes. Tumor growth inhibition is monitored, and biomarkers of apoptosis and cell proliferation are assessed in tumor tissues.
|
| ADME/Pharmacokinetics |
Lycorine hydrochloride monohydrate has a molecular formula of C16H20ClNO5 and a molecular weight of 341.79. The hydrochloride monohydrate form enhances solubility and stability for experimental applications. The compound should be stored at 4°C, sealed, away from moisture.
|
| Toxicity/Toxicokinetics |
The toxicity profile of lycorine is consistent with its mechanism as a protein synthesis inhibitor. High doses may cause gastrointestinal and neurological effects. The compound has been evaluated for safety in preclinical studies. Its therapeutic window is being investigated for potential oncology applications.
|
| Additional Infomation |
Lycorine hydrochloride monohydrate is a biochemical reagent used in cancer research. It has demonstrated antiviral and antitumor activities in vitro and in animal models. The compound is also known as lycorine HCl monohydrate. It is used to study apoptosis, cell proliferation, and protein synthesis inhibition pathways.
|
| Molecular Formula |
C16H20CLNO5
|
|---|---|
| Molecular Weight |
341.7867
|
| Exact Mass |
341.103
|
| CAS # |
6150-58-9
|
| Related CAS # |
Lycorine;476-28-8
|
| PubChem CID |
70446239
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
215 °C(dec.)
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
23
|
| Complexity |
481
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
Cl[H].O([H])[C@]1([H])[C@]([H])(C([H])=C2C([H])([H])C([H])([H])N3C([H])([H])C4=C([H])C5=C(C([H])=C4[C@@]1([H])[C@]32[H])OC([H])([H])O5)O[H].O([H])[H]
|
| InChi Key |
ZOERACVSGIQXBP-CANOEZFNSA-N
|
| InChi Code |
InChI=1S/C16H17NO4.ClH.H2O/c18-11-3-8-1-2-17-6-9-4-12-13(21-7-20-12)5-10(9)14(15(8)17)16(11)19;;/h3-5,11,14-16,18-19H,1-2,6-7H2;1H;1H2/t11-,14-,15+,16+;;/m0../s1
|
| Chemical Name |
(1S,17S,18S,19S)-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraene-17,18-diol;hydrate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9258 mL | 14.6289 mL | 29.2577 mL | |
| 5 mM | 0.5852 mL | 2.9258 mL | 5.8515 mL | |
| 10 mM | 0.2926 mL | 1.4629 mL | 2.9258 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
